HOUSTON -- Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today successful treatment of the first patients in the ...

Houston medical device company Procyrion has raised $30 million to support clinical trials of a device that would treat patients suffering from both heart failure and worsening kidney function.

WICHITA, Kan. (KSNW) — Patients who are experiencing a particular form of heart and kidney impairment that isn’t responding to traditional treatment may soon benefit from a new, potentially ...

HOUSTON, Sept. 7, 2023 /PRNewswire/ -- Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today it has successfully ...

Procyrion is developing what it says is the first catheter-deployed micropump for the heart. It's now nabbed a $10 million Series B round to back clinical development of its tiny, chronic heart ...

A Houston medical device company received a special designation from the U.S. Food and Drug Administration that should speed its development of a pump that treats both heart failure and worsening ...

HOUSTON, Nov. 30, 2023 /PRNewswire/ -- Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced the enrollment of the first ...

HOUSTON, March 21, 2023 /PRNewswire/ -- Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today that use of its ...

Describe your device and how it will benefit healthcare. Procyrion Inc. is working to give chronic heart failure patients a solution by developing the world's first catheter-deployed circulatory ...

An intra-aortic pump delivered by catheter holds promise to help heart failure patients' hearts rest and heal. But it needed the right motor. Qmed Staff Houston-based Procyrion has an intra-aortic ...

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below: Receive the the latest news, research, and presentations from major meetings ...